Cargando…
Impact of the selective A2(A)R and A2(B)R dual antagonist AB928/etrumadenant on CAR T cell function
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a bottleneck preventing treatment success of CAR T cells in a broader range of tumours....
Autores principales: | Seifert, Matthias, Benmebarek, Mohamed-Reda, Briukhovetska, Daria, Märkl, Florian, Dörr, Janina, Cadilha, Bruno L., Jobst, Jakob, Stock, Sophia, Andreu-Sanz, David, Lorenzini, Theo, Grünmeier, Ruth, Oner, Arman, Obeck, Hannah, Majed, Lina, Dhoqina, Dario, Feinendegen, Manouk, Gottschlich, Adrian, Zhang, Jin, Schindler, Ulrike, Endres, Stefan, Kobold, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726885/ https://www.ncbi.nlm.nih.gov/pubmed/36266575 http://dx.doi.org/10.1038/s41416-022-02013-z |
Ejemplares similares
-
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023) -
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023) -
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis
por: Briukhovetska, Daria, et al.
Publicado: (2023) -
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
por: Cadilha, Bruno L., et al.
Publicado: (2021) -
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
por: Stoiber, Stefan, et al.
Publicado: (2019)